TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22634908
Drug: Group BC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group BC - bupivacaine 0.125% and clonidine 5 μg/ml
Study: 22634908
Drug: Group MC
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group MC - morphine 0.1 mg/ml and clonidine 5 μg/ml
Study: 10230950
Drug: Methylprednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (1 g administered 30 minutes before CPB)
Study: 9783757
Drug: Diclofenac 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 100 mg slow release
Study: 8628979
Drug: Naproxen 750-1000
Normalized name: naproxen 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 750-1000 mg
Study: 6118170
Drug: Brompheniramine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brompheniramine (12 mg)
Study: 6118170
Drug: Carbinoxamine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbinoxamine (12 mg)
Study: 6351890
Drug: Clemastine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine (1 mg)
Study: 6118170
Drug: Phenylpropanolamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylpropanolamine (50 mg)
Study: 31087200
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg) every 2 weeks until disease progression or toxicity requiring study discontinuation
Study: 11752122
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of MDMA plus 0.8 g/kg ethanol
Study: 11752122
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of MDMA
Study: 24838369
Drug: 0.8 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/kg of ethanol
Study: 9615259
Drug: omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 20 mg om
Study: 9615259
Drug: omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 10 mg om
Study: 3549473
Drug: ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranitidine 150 mg bd
Study: 882110
Drug: Penicillin G
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin G administered intravenously every four hours for a total of 50,000 U per kilogram per day
Study: 31512830
Drug: Acid etching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid etching with 98% concentrated sulfuric acid for 60, 120, and 300 s (groups E, F, G)
Study: 31512830
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group H (no surface treatment)
Study: 26016146
Drug: Palliative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Palliative radiotherapy course with a fractional dose of 3 Gy to 42 Gy SOD (SDeq 51 Gy) in group 1 (20 patients)
Study: 26016146
Drug: Radiotherapy using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy using dynamic dose fractionation: fractional doses of 4, 3, and 2 Gy to 51 Gy SDeq in group 2 (20 patients)
Study: 26016146
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment using dynamic dose fractionation: fractional doses of 4, 3, and 2 Gy to 56 Gy SDeq and chemotherapy (Xeloda or ftorafur) in group 3 (20 patients)
Study: 23167953
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg vitamin C
Study: 21706269
Drug: Vascular endothelial
Normalized name: Vascular endothelial growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vascular endothelial growth factor receptor-2 (VEGFR-2) expression in malignant cases
Study: 16567439
Drug: SonoVue contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: SonoVue contrast agent administration
Study: 10781116
Drug: Mivacurium 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 0.04 mg.kg‐1
Study: 8640163
Drug: Sequential IL-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential IL-3 -> G-CSF (Arm 2)
Study: 8640163
Drug: Sequential IL-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential IL-3 -> GM-CSF (Arm 3)
Study: 8640163
Drug: Combined IL-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined IL-3 + G-CSF (Arm 4)
Study: 8640163
Drug: GM-CSF after
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF after PBSC infusion
Study: 1451712
Drug: ibuprofen-codeine 200
Normalized name: codeine / ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen-codeine 200 mg : 30 mg
Study: 1451712
Drug: acetylsalicylic acid-codeine
Normalized name: codeine and acetylsalicylic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetylsalicylic acid-codeine 500 mg : 30 mg
Study: 1451712
Drug: codeine 30
Normalized name: codeine 30 MG
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: codeine 30 mg
Study: 22451451
Drug: Valsartan (80-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (80-160 mg per day)
Study: 22451451
Drug: Non-RAS inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-RAS inhibitor treatment
Study: 19121416
Drug: Zoledronate 4
Normalized name: zoledronic acid 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoledronate 4 mg
Study: 15207898
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg per day)
Study: 11830920
Drug: Tamoxifen plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen plus CMF (C 500 mg/m2, M 40 mg/m2, F 600 mg/m2 on days 1st and 8th q 28 day for 6 cycles)
Study: 9552047
Drug: Adjuvant interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant interferon alfa-2a treatment (3 mIU subcutaneously daily for 3 weeks, then 3 mIU three times per week for 1 year)
Study: 7917369
Drug: Daily low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily low-dose carboplatin (30 mg/m2 on days 1-5, weeks 1, 3, 5, and 7)
Study: 7917369
Drug: Daily low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily low-dose carboplatin (up to 55 mg/m2)
Study: 7917369
Drug: Daily low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily low-dose carboplatin and radiotherapy (70 Gy)
Study: 7917369
Drug: Daily low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily low-dose carboplatin and radiotherapy (40-45 mg/m2)
Study: 7917369
Drug: Daily low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily low-dose carboplatin and radiotherapy
Study: 31977865
Drug: Afatinib 40
Normalized name: afatinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 40 mg/day plus HAD-B1 972 mg
Study: 31977865
Drug: Afatinib 40
Normalized name: afatinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 40 mg/day plus HAD-B1 1944 mg
Study: 29457215
Drug: Inhalational agent-opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalational agent-opioid anaesthesia
Study: 23921860
Drug: Lidocaine submucosal
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine submucosal injection (1.8 mL of 2% lidocaine with 1:100,000 epinephrine)
Study: 23921860
Drug: Lidocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine spray (four puffs of 10% lidocaine)
Study: 21751432
Drug: Salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone propionate 50/100 µg bd (SFC)
Study: 21751432
Drug: Montelukast 5
Normalized name: montelukast 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 5 mg od (MON)
Study: 18154127
Drug: Dicarbamin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dicarbamin 100 mg/day
Study: 18154127
Drug: ABVD chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABVD chemotherapy plus dicarbamin
Study: 9684947
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg of hypericum extract with 5.0% hyperforin, once a day for 8 days
Study: 9684947
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg of hypericum extract with 0.5% hyperforin, once a day for 8 days
Study: 2736988
Drug: EACA (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: EACA (5 g prior to skin incision, followed by 1 g/h for 6 to 8 h)
Study: 2736988
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline solution administered in the same fashion)
Study: 29281101
Drug: Sildenafil (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (40 mg three times daily)
Study: 18326282
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg a day for 4 months
Study: 18326282
Drug: Losartan in
Normalized name: Product containing losartan in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan in combination with non-drug means
Study: 16585984
Drug: 308-nm UVB
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 308-nm UVB therapy
Study: 16585984
Drug: cream PUVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: cream PUVA therapy
Study: 6133544
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg temazepam
Study: 24867068
Drug: DHEA 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 75 mg once a day for 8 weeks before and during IVF treatment
Study: 19803239
Drug: Needle‐sticking method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle‐sticking method combined with single‐finger meditation pushing therapy at pain points
Study: 16409461
Drug: BAY 59-7939
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 59-7939 2.5 mg b.i.d.
Study: 16409461
Drug: BAY 59-7939
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 59-7939 5 mg b.i.d.
Study: 16409461
Drug: BAY 59-7939
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 59-7939 10 mg b.i.d.
Study: 16409461
Drug: BAY 59-7939
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 59-7939 20 mg b.i.d.
Study: 16409461
Drug: BAY 59-7939
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 59-7939 30 mg b.i.d.
Study: 16409461
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg once daily (control)
Study: 16241946
Drug: BAY 59-7939
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 59-7939 (all doses)
Study: 11751721
Drug: Propranolol (0.21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.21 mg/kg total intravenous dose in 15 minutes)
Study: 9480620
Drug: Betadine vaginal
Normalized name: Betadine Vaginal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betadine vaginal suppository (200 mg polyvidonum‐iodine PVP) for 7 days
Study: 7685895
Drug: Steroid-eluting lead
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-eluting lead
Study: 3327654
Drug: diet plus
Normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: diet plus drug (colestipol plus niacin)
Study: 31604475
Drug: lacosamide (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: lacosamide (up to 400 mg/day)
Study: 17688642
Drug: DTPa‐HBV‐IPV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa‐HBV‐IPV vaccine
Study: 12392812
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (untreated participants in wait-list, no-treatment, and placebo conditions)
Study: 8184493
Drug: Intravesical Bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical Bacillus Calmette‐Guérin (BCG) treatment for carcinoma in situ (CIS)
Study: 8184493
Drug: Intravesical Bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical Bacillus Calmette‐Guérin (BCG) treatment for prophylaxis
Study: 8184493
Drug: Intravesical Bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical Bacillus Calmette‐Guérin (BCG) treatment for tumor(s)
Study: 2684039
Drug: Daily 6-mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily 6-mercaptopurine and weekly methotrexate (neutropenic group)
Study: 2684039
Drug: Daily 6-mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily 6-mercaptopurine and weekly methotrexate (non-neutropenic group)
Study: 1093670
Drug: Diethylstilbestrol 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylstilbestrol 5.0 mg/day
Study: 1093670
Drug: Diethylstilbestrol 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylstilbestrol 1.0 mg/day
Study: 1093670
Drug: Early endocrine
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early endocrine treatment
Study: 26313133
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical treatment for ACS (N=123)
Study: 22379905
Drug: Sevoflurane and
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane and extended-release epidural anesthesia with Ropivacaine 0.3%
Study: 25994838
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg once daily
Study: 15475417
Drug: Treatment regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment regimen 1
Study: 15475417
Drug: Treatment regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment regimen 2
Study: 10600077
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment (ART) using hand instruments
Study: 8757381
Drug: Ibuprofen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (500 mg suppositories administered 12 and 2 hours before surgery, and every 8 hours until the third postoperative day)
Study: 8757381
Drug: Ibuprofen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (500 mg suppositories)
Study: 8757381
Drug: Placebo (suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (suppositories administered 12 and 2 hours before surgery, and every 8 hours until the third postoperative day)
Study: 6807681
Drug: Oxprenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (100 mg) for 24 hours
Study: 6807681
Drug: Indomethacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (200 mg) for 24 hours
Study: 6807681
Drug: Oxprenolol +
Normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxprenolol + Indomethacin (100 + 200 mg) for 24 hours
Study: 22990854
Drug: L. reuteri
Normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. reuteri NCIMB 30242 capsules
Study: 20486914
Drug: Mycophenolate therapy
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mycophenolate therapy
Study: 11777716
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine ophthalmic solution 0.5%
Study: 8625175
Drug: Sho-saiko-to (TJ-9)
Normalized name: erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sho-saiko-to (TJ-9) at a daily oral dose of 7.5 g
Study: 8625175
Drug: Conventional drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drugs (Control)
Study: 31241992
Drug: Spironolactone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (50 mg and 100 mg)
Study: 25491792
Drug: JNJ‐39758979 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐39758979 100 mg
Study: 25491792
Drug: JNJ‐39758979 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐39758979 300 mg
Study: 21480979
Drug: Melatonin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (50 mg/kg BW)
Study: 14692930
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy without cold air analgesia
Study: 7506180
Drug: Nimesulide suspension
Normalized name: nimesulide Oral Suspension
DrugBank: Nimesulide (DB04743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide suspension (1.5 mg/kg 3 times daily)
Study: 7506180
Drug: Paracetamol syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol syrup (10 mg/kg 4 times daily)
Study: 2882288
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (30 mg for children under 5, 60 mg for older children)
Study: 28472976
Drug: DHEA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA supplementation (25 mg three times a day for 8 weeks)
Study: 16430794
Drug: Rofecoxib 50
Normalized name: rofecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 50 mg administered perioperatively
Study: 16430794
Drug: Rofecoxib 50
Normalized name: rofecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 50 mg administered only postoperatively
Study: 10638466
Drug: Total Parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Parenteral Nutrition (TPN) for 10 days preoperatively and 9 days postoperatively
Study: 10638466
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no preoperative nutrition, 940 kcal nonprotein plus 85 g amino acids postoperatively)
Study: 9375889
Drug: 1 mg/day
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/day of liquid folic acid
Study: 1608268
Drug: 5% methanolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% methanolic leaf extract cream of Solanum chrysotrichum
Study: 1608268
Drug: Miconazole treatment
Normalized name: Miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole treatment (control group)
Study: 3929513
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone releasing factor (GRF) 100 micrograms
Study: 28094169
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24IU twice daily)
Study: 21493740
Drug: Icodextrin (ICO)
DrugBank: Icodextrin (DB00702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Icodextrin (ICO) - treated with 1.5 or 2.0 L of 7.5% icodextrin‐containing solutions
Study: 21493740
Drug: Glucose (GLU)
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose (GLU) - treated with 8 L of 1.5% or 2.5% glucose
Study: 18652267
Drug: Ceramic Primer/LinkmaxHV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceramic Primer/LinkmaxHV (CP/LMHV) with 37% phosphoric acid treatment (PA)
Study: 18652267
Drug: Monobond S/VariolinkIIHV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monobond S/VariolinkIIHV (MBS/VLIIHV) with 37% phosphoric acid treatment (PA)
Study: 18652267
Drug: MBS/HB/VLIIHV with
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBS/HB/VLIIHV with various surface treatments
Study: 18652267
Drug: All combined
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All combined groups of ceramic surface treatment and resin bonding system
Study: 29889285
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine in combination therapy (HD-ECM)
Study: 29889285
Drug: Standard combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard combination therapy (ECM)
Study: 27321554
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (CG)
Study: 21358207
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel (30 mg/m² on days 1, 8, and 15; q4w)
Study: 21358207
Drug: Standard docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard docetaxel (75 mg/m² every 3 weeks; q3w)
Study: 16616726
Drug: Neuroendocrine hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neuroendocrine hormone responses
Study: 12682721
Drug: Filgrastim (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim (1 micro g.kg.24 h) for 10 days as a continuous infusion
Study: 6738337
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of 10 mg/kg metrifonate
Study: 6738337
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of 10 mg/kg metrifonate
Study: 6738337
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of 10 mg/kg metrifonate
Study: 30761523
Drug: Racecadotril (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racecadotril (100 mg) - acute administration
Study: 30761523
Drug: Racecadotril (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racecadotril (100 mg; t.i.d.) - chronic administration for 14 days
Study: 11751710
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - acute administration
Study: 30761523
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - chronic administration for 14 days
Study: 29070025
Drug: Daylight photodynamic
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daylight photodynamic therapy (DL-PDT)
Study: 28222225
Drug: Conventional photodynamic
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional photodynamic therapy (C-PDT)
Study: 27115126
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements (LNS) 200 g daily during the first 3 months of ART
Study: 24961851
Drug: Daily intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intake of DEHP estimated using the urine volume (UV) model
Study: 24961851
Drug: Daily intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intake of DEHP estimated using the urine creatinine-excretion (UCE) model